Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
Management to Host Conference Call
BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release first quarter 2023 financial results and business updates on Monday, May 15, 2023. The Company will host a webcast that day at 8:30 a.m. Eastern Time to discuss the results and updates.
The live conference call may be accessed and on the Company’s under Events and Presentations.
The archived webcast will be available on the Company’s website beginning approximately two hours after the event for 90 days.
About Minerva Neurosciences
Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company focused on developing product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options. Minerva’s portfolio of compounds includes roluperidone (MIN-101), for negative symptoms of schizophrenia, and MIN-301, in pre-clinical development for Parkinson’s disease. For more information, please visit our .
For more information:
Investor inquiries:
Fred Ahlholm
CFO, Minerva Neurosciences
Media Inquiries:
Helen Shik
Principal, Shik Communications LLC
